Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,117
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
Weak Housing Data Helps Push U.S. Stocks Lower
U.S. stocks drifted lower on Tuesday as weaker-than-expected housing data weighed on investor sentiment. Investors will have more economic data to digest as manufacturing and consumer confidence reports also are set to be released.
Top Equities Stories Of The Day
JAL Customer Data Target of Cyber Attack
Bank Branches in U.S. Dip to Lowest Since 2005
IPO Scorecard: Update on Selected Initial Stock Offerings
Bank Branches in U.S. Decline to Lowest Level Since 2005
Starboard Pushes For Potential Yahoo-AOL Tie-Up -- 5th Update
Intel Invests in Chinese Chip Maker -- Update
Bank Stocks Lift FTSE 100; Sports Direct Drops
Starboard Pushes For Potential Yahoo-AOL Tie-Up -- 5th Update
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 182274 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist